Fecal microbiota transplantation in a toddler after heart transplant was a safe and effective treatment for recurrent Clostridiodes difficile infection: A case report.
Clostridium difficile
fecal microbiota transplant
pediatric heart transplant
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
28
05
2019
revised:
19
08
2019
accepted:
01
09
2019
pubmed:
17
10
2019
medline:
26
1
2021
entrez:
17
10
2019
Statut:
ppublish
Résumé
Pediatric recipients of SOT have a significantly increased risk of Clostridiodes (formerly Clostridium) difficile infection (CDI), which is associated with adverse outcomes after SOT. Alterations to the intestinal microbiota community structure increase the risk of CDI. FMT is a safe and effective treatment for recurrent CDI in immunocompetent children and adults. While there are increasing data that FMT in immunosuppressed patients is safe and effective without increased risk of infection, data regarding safety and efficacy of FMT in children after SOT are limited. To our knowledge, we report the youngest immunocompromised patient to undergo FMT and the third overall case of FMT in a child after HTx. Our patient presented with five episodes of rCDI in 6 months, and 16S rRNA genetic analysis revealed significant loss of overall microbiota community structure and diversity prior to FMT compared with a donor and a healthy, age-matched control. After FMT, marked and prolonged (at least 16 months) shifts in the recipient microbiota community structure and diversity were evident, approaching that of donor and healthy, age-matched control. FMT was well tolerated, restored microbial diversity without any graft or transplant complications, and prevented further rCDI episodes after more than 4 years of follow-up.
Identifiants
pubmed: 31617299
doi: 10.1111/petr.13598
pmc: PMC6982574
mid: NIHMS1051678
doi:
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13598Subventions
Organisme : NIAID NIH HHS
ID : U01 AI124290
Pays : United States
Organisme : NIH HHS
ID : U01-AI24290
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
J Pediatr. 2018 Mar;194:123-127.e1
pubmed: 29198534
Transplantation. 2014 Oct 15;98(7):697-705
pubmed: 25289916
Curr Opin Organ Transplant. 2008 Dec;13(6):592-600
pubmed: 19060548
Am J Transplant. 2014 Feb;14(2):477-80
pubmed: 24433460
Clin Gastroenterol Hepatol. 2019 Apr 19;:null
pubmed: 31009795
Front Cardiovasc Med. 2017 Apr 04;4:17
pubmed: 28421185
Pediatr Infect Dis J. 2011 Jul;30(7):580-4
pubmed: 21233782
Can J Gastroenterol Hepatol. 2018 Sep 2;2018:1394379
pubmed: 30246002
Sci Transl Med. 2018 Sep 26;10(460):
pubmed: 30257956
Transpl Infect Dis. 2012 Oct;14(5):540-7
pubmed: 22726461
Aliment Pharmacol Ther. 2016 Feb;43(4):445-57
pubmed: 26662643
Transpl Infect Dis. 2016 Oct;18(5):706-713
pubmed: 27492796
Blood. 2014 Aug 14;124(7):1174-82
pubmed: 24939656
Best Pract Res Clin Haematol. 2015 Jun-Sep;28(2-3):155-61
pubmed: 26590773
Transpl Infect Dis. 2016 Feb;18(1):31-6
pubmed: 26538348
J Pediatr Gastroenterol Nutr. 2015 Jan;60(1):23-6
pubmed: 25162365
Curr Gastroenterol Rep. 2019 Feb 28;21(4):8
pubmed: 30815766
Am J Gastroenterol. 2012 Jul;107(7):1079-87
pubmed: 22450732
Am J Gastroenterol. 2014 Jul;109(7):1065-71
pubmed: 24890442
Transpl Infect Dis. 2018 Dec;20(6):e12983
pubmed: 30155958
Am J Transplant. 2019 Feb;19(2):488-500
pubmed: 29920927
Transplantation. 2012 May 27;93(10):1051-7
pubmed: 22441318
Anaerobe. 2016 Oct;41:37-43
pubmed: 27180006
J Infect. 2012 Feb;64(2):131-47
pubmed: 22178989
J Infect Chemother. 2015 Apr;21(4):230-7
pubmed: 25703532
Clin Gastroenterol Hepatol. 2011 Dec;9(12):1044-9
pubmed: 21871249
Transpl Infect Dis. 2018 Dec;20(6):e12967
pubmed: 30011107